About Alitair pharmaceuticals

About company

Alitair is a specialty pharmaceutical company with a focus on the respiratory space. Currently, we are developing two orphan drugs for bronchiectasis. We expect to begin phase II clinical trials for both compounds within the next 6 months. We also have products under development for prescription and over-the-counter cough treatment. Our lead cough candidate is a solid oral dosage form of benzonatate which is protected by a composition-of-matter patent. Currently, Alitair has four issued patents and we expect to expand our patent portfolio in the near future.